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Abstract
Epstein-Barr Virus (EBV) can establish latent infections with distinct gene expression patterns referred to as latency types.
These different latency types are epigenetically stable and correspond to different promoter utilization. Here we explore the
three-dimensional conformations of the EBV genome in different latency types. We employed Chromosome Conformation
Capture (3C) assay to investigate chromatin loop formation between the OriP enhancer and the promoters that determine
type I (Qp) or type III (Cp) gene expression. We show that OriP is in close physical proximity to Qp in type I latency, and to
Cp in type III latency. The cellular chromatin insulator and boundary factor CTCF was implicated in EBV chromatin loop
formation. Combining 3C and ChIP assays we found that CTCF is physically associated with OriP-Qp loop formation in type I
and OriP-Cp loop formation in type III latency. Mutations in the CTCF binding site located at Qp disrupt loop formation
between Qp and OriP, and lead to the activation of Cp transcription. Mutation of the CTCF binding site at Cp, as well as
siRNA depletion of CTCF eliminates both OriP-associated loops, indicating that CTCF plays an integral role in loop formation.
These data indicate that epigenetically stable EBV latency types adopt distinct chromatin architectures that depend on CTCF
and mediate alternative promoter targeting by the OriP enhancer.
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Introduction
Epstein-Barr virus (EBV) is a human gammaherpesvirus that is
the etiological agent of infectious mononucleosis and is commonly
associated with B-cell lymphomas, as well as epithelial malignan-
cies [1,2]. EBV latent infection is observed in endemic Burkitt’s
lymphoma (BL), the majority of Hodgkin’s lymphomas (HL) and
in lymphoproliferative diseases associated with immunosuppres-
sion [3]. During latency the EBV genome is maintained as a
multicopy, chromatinized episome that can adopt one of four
different gene expression patterns. These metastable gene
expression patterns are generally referred to as latency types and
are classified on the basis of EBNA and LMP protein expression
[4]. Type 0 latency is defined as latency with no viral gene
expression and is found in non-dividing B-cells [5]. In Type I
latency, which is observed in BL and BL-derived cell lines, as well
as in memory B-cells in a healthy host, EBNA1 is the only viral
gene that is expressed [6,7,8,9,10]. In undifferentiated nasopha-
ryngeal carcinoma (NPC), EBV-associated gastric carcinoma, HL,
and T cell lymphomas EBV expresses LMP1 and LMP2 along
with EBNA1 and this pattern is referred to as latency type II
[11,12,13,14,15,16,17,18,19]. In immunoblastic lymphomas asso-
ciated with immunosuppression and in vitro immortalized lympho-
blastoid cell lines (LCLs) EBV is able to express all of the known
latency associated genes, EBNA-1, -2, -3A, -3B, -3C, -LP, LMP1
and LMP2 [20]. These different patterns of gene expression are
epigenetically stable, in that they are maintained over multiple cell
divisions, and generally reflect developmental fate-associated
properties of the host-cell.
Latency type gene expression patterns typically correspond to
distinct primary transcripts that are initiated from different viral
promoters [21,22,23,24]. In type I latency EBNA1 is transcribed
starting from Qp in the BamHI/Q region of the EBV genome,
while in type III latency the polycistronic mRNA for EBNA
proteins is initiated from Cp located in the BamHI C region of the
EBV genome [22,24,25,26]. Promoter selection is a critical step
for establishing which gene expression program EBV adopts. Both
viral and cellular transcription factors are known to regulate these
alternative promoters [27], yet many questions still remain.
For example, EBNA1 binding sites at OriP serve as an essential
enhancer of Cp in the establishment of type III latency, but it is
not known how this enhancer physically targets Cp rather than Qp
[28,29,30]. It is also known that EBNA1 binding to the Qp
transcription initiation site inhibits Qp transcription in type III
latency [31], but it is not known how this repression is reversed
during the transition to type I latency. Furthermore, epigenetic
modifications are known to play an important role in regulating
promoter selection [32,33]. In type I latency Cp is enriched for
deacetylated histones and hypermethylated DNA, while Qp is
associated with acetylated histones and elevated H3meK4
[34,35,36,37]. In contrast, in type III latency H3meK4 levels
are high at Cp along with histone acetylation and DNA
hypomethylation while Qp lacks histone modifications associated
with active transcription [35,37]. How these DNA binding factors
and chromatin modifications orchestrate the mutually exclusive
alternative promoter selection of Cp or Qp remains an important
unanswered question for understanding EBV latency control
mechanisms.
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chromosome structures, including DNA loops, chromatin do-
mains, and insulators, play an important role in gene expression
programming [38,39]. The use of new techniques such as
Chromosome Conformation Capture (3C) and variations of this
assay revealed a complex and diffuse network of long-distance
interactions between DNA regions both intra- and inter-
chromosomal [40,41,42,43]. Many of these chromatin loops are
dynamic and may reflect alternative genome packaging into the
nucleus, while other interactions may reflect programmed long-
distance interactions that play a crucial role in gene regulation.
Identification of cellular factors that regulate loop-formation and
long distance interactions support the importance of three-
dimensional structures in regulating gene expression [44,45].
The CCCTC-binding factor (CTCF) has been reported in
several studies to be involved in promoting and regulating
chromatin loop formation [46,47,48,49,50]. CTCF is a nuclear
DNA binding protein that contains eleven zinc fingers and is well
conserved among higher eukaryotes [51,52,53]. CTCF is involved
in different functions including chromatin boundary formation,
DNA loop formation, transcriptional activation and repression,
and promoter-enhancer blocking activity [46,47]. In EBV, CTCF
binds at several key regulatory regions [35]. In particular, CTCF
can bind between OriP and Cp to negatively regulate transcription
initiating at Cp in type I latency [54]. In addition, CTCF can bind
upstream of Qp, and this binding is crucial for maintaining
transcription activation and protecting Qp from epigenetic
silencing [37]. However, the role of CTCF in EBV chromatin
conformation has not been addressed. Here, we use 3C and
variations of 3C to probe the conformations of the EBV latency
control regions in different latency types.
Results
3C analyses of EBV type I and type III genomes reveal
distinct conformations of the OriP enhancer region
To determine if the differences in EBV latency type gene
expression correlate with differences in three-dimensional organi-
zation of the EBV episome, we employed the 3C assay (Fig. 1).
EBV positive B-cell lines with stable type I (Mutu I) or type III
(Mutu-LCL) latency types were cross-linked with formaldehyde for
30 min and then processed for 3C after fragmentation with MseI
restriction enzyme, which generates 342 fragments ranging from
4b p t o ,4 kbp (Fig. 1A and B). Primers located in MseI
fragments containing Cp (10894–11202) or Qp (49780–50493)
were used as anchors for the PCR analysis of 3C interactions with
several other regions of the EBV genome, including FR, DS, and
the CTCF binding site at position 10.6 kb situated between DS
and Cp [54]. A third anchor primer at position 35401–36017 was
used as a control for 3C product specificity (Fig. 1B). As a positive
control for primer efficiency we used a random ligation mixture of
MseI digested EBV bacmid DNA in order to contain every
possible combination of ligation products.
The Qp promoter is active in type I latency, and silenced in type
III latency (Fig. 1A). When Qp anchor primers were used for 3C,
we observed a strong ligation product between Qp and the OriP
region in Mutu (Type I) (Fig. 1C, top panel). Interestingly, Qp
interactions were identified for both DS (,9000) and FR (,7000)
elements of OriP. Qp also interacted with the CTCF-binding site
upstream the Cp promoter (,10,600). Qp did not form detectable
3C ligation products with several other regions of the EBV
genome, including regions at 11, 11.3, 36, 113 and 126 kb on the
EBV genome. In contrast to type I latency, Qp did not form any
3C products in type III latency (Mutu-LCL), where Qp is
transcriptionally silent (Fig. 1C, middle panel). These findings
indicate that the 3C ligation products between Qp and OriP
region correlate with transcription activity of Qp. All ligation
products could be detected in control reactions with bacmid DNA
(Fig. 1C, lower panel). These findings suggest that Qp forms
specific DNA looping interactions with OriP and the CTCF
binding site upstream of Cp in type I cells, but not in type III cells.
We next examined the three dimensional architecture of Cp in
both type I and type III (Fig. 1C). In type I latency (Mutu I), where
Cp is transcriptionally silent, the Cp anchor failed to form any
detectable 3C products with acceptor primers (Fig. 1D, top panel).
In type III latency (Mutu-LCL), where Cp is transcriptionally
active, we found a predominant 3C interaction between Cp and
the DS element of OriP (Fig. 1D, middle panel). All primer sets
were capable of amplifying ligation products from control bacmid
DNA (Fig. 1D, lower panel).
To verify that 3C interactions between Qp or Cp with OriP
were specific and not due to a generic conformation of OriP in
type I or type III, we used a primer at 35401 (a region equidistant
from both Cp and Qp) as an anchor for the PCR analysis (Fig. 1E).
The 35401 anchor primer was unable to form 3C interactions with
OriP or any other region of the EBV genome assayed in type I
(Fig. 1E, top panel) or type III (Fig. 1E, middle panel) cells. All
primer sets were capable of generating PCR products from control
ligation reactions with EBV bacmid DNA (Fig. 1E, lower panel).
Furthermore, all major 3C products were gel purified, subjected to
direct DNA sequencing, and validated for correct ligation products
(data not shown). These finding indicate that the 3C products
formed between Qp and OriP in type I, and Cp and OriP in type
III cells, are sequence and cell-type specific interactions.
To validate the conventional PCR data and to better quantify
the 3C interaction products, we analyzed the chromatin
conformation by real time PCR using a different set of primer
pairs (Fig. 2). When Qp anchor primers were assayed, interactions
with OriP (FR and DS) and CTCF-Cp binding site (10.6) were
observed in type I (Mutu), but not in type III (Mutu-LCL) (Fig. 2A).
When Cp anchor primers were used, an interaction with DS was
detected in type III (Mutu-LCL), but not in type I (Mutu) (Fig. 2B).
The control anchor at 35.6kb failed to form any specific 3C
Author Summary
Epstein-Barr Virus (EBV) latent infection is associated with
several human malignancies. The viral genes expressed
during latent infection can vary depending on host cell or
tumor type. The different gene expression programs,
referred to as latency types, are determined by alternative
viral promoter usage. In this work, we investigate how
differential DNA loop formation regulates viral promoter
selection in different latency types. We use chromatin
conformation capture methods to demonstrate that the
transcriptional enhancer at OriP forms a stable loop with
one of two different promoters, depending on the latency
type. In type I latency, OriP forms a loop with the active Q
promoter (Qp). In type III latency, OriP forms a loop with
the active C promoter (Cp). Loop formation was mediated,
in part, by CTCF binding sites located within the loops.
Mutation in the CTCF binding site located at Qp caused a
loss of OriP-Qp loop formation, a loss of Qp transcription,
and a reactivation of Cp transcription from an alternative
loop formed with OriP-Cp. These findings indicate that
OriP loop formation is an integral component of promoter
selection, and that chromatin conformation may deter-
mine EBV latency type.
EBV Chromatin Conformation
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interaction can be detected at regions immediately adjacent to the
anchor primers, which is expected in quantitative 3C reactions,
but does not indicate a specific chromatin conformation [55]. The
specificity of the primer set was tested by agarose gel electropho-
resis and dissociation curve analysis (Figures S1-4).
OriP binding factors EBNA1, ORC2 and TRF2 interact with
active promoters for each latency type
To validate the presence of a chromatin loop between OriP and
either Cp or Qp promoters in their respective latency types, we
used a modified Chromatin Immunoprecipitation (ChIP) assay
(Fig. 3). We reasoned that OriP binding factors should associate
with either Cp or Qp if they were in close physical proximity due
to a DNA loop between these different DNA loci. To measure
these potentially indirect protein-DNA interactions, we increased
the crosslink time as long as for 3C (30 min) in order to preserve
any chromatin loop formation. Previous studies have demonstrat-
ed that cellular proteins TRF2 and ORC2, and the viral protein
EBNA1 bind at the DS region of OriP in both type I and type III
cells [56,57]. We therefore assayed TRF2, ORC2, and EBNA1 for
interactions with either Qp or Cp using this extended cross-linking
ChIP assay. The DNA was analyzed by real time PCR using
primers specific for different regions of the EBV genome. We
found a significant enrichment of ORC2, TRF2 and EBNA1 at
Cp in type III but not in type I (Fig. 3A), suggesting that the OriP
region is in close proximity to the active (type III) Cp, in
agreement with the 3C data. In contrast, ORC2 and TRF2 were
enriched at Qp only in type I cells, where Qp is active (Fig. 3B).
EBNA1 was able to bind at Qp both in type I and type III,
consistent with the known sequence-specific binding of EBNA1 at
Qp. It is worth noting that Qp is ,40 kb from the OriP region
and that these ChIP results are consistent with the chromatin loop
observed in the 3C assay. As a positive control we tested the
enrichment of all three proteins at the DS region of OriP (Fig. 3C).
We found that EBNA1, ORC2, and TRF2 bound with high
occupancy (.100 fold enrichment) at DS in type I and type III
latencies. To rule out any non-specific binding caused by the
increase in cross-linking time we evaluated the binding profile for
all three proteins at OriLyt (Fig. 3D). We did not detect any
significant enrichment for EBNA1, ORC2, or TRF2 with OriLyt
in either latency type, indicating that the extended cross-linking
time did not cause non-specific ChIP interactions.
CTCF is involved in chromatin loop formation in EBV
latency types
CTCF can bind upstream of both Cp and Qp, and influence
their transcription activity [37,54]. Since CTCF has been
Figure 1. OriP region forms alternative chromatin loops in type I and type III latency types. A) Schematic of type I and type III promoter
usage and relative position of OriP, Cp, and Qp are indicated. Green boxes indicate known CTCF binding sites. B) Schematic of MseI restriction site
map and the anchor primers used for Qp, Cp, and control. EBV genome coordinates for each anchor primer are indicated. C) 3C PCR analysis using the
Qp anchor primers and several acceptor regions of EBV genome for FR, DS, 10.6, 11 11.3, 36, 113, and 126 kbp. Representative gel images for Mutu I
(top), Mutu-LCL (middle) or control bacmid ligation mixtures (lower) are indicated. D) Representative gel images of 3C PCR analysis using the Cp
anchor primer and several acceptor regions of the EBV genome as indicated. E) Representative gel images of 3C PCR analysis using the anchor primer
within the fragment chosen as control and several regions of the EBV genome, as indicated.
doi:10.1371/journal.ppat.1002180.g001
EBV Chromatin Conformation
PLoS Pathogens | www.plospathogens.org 3 July 2011 | Volume 7 | Issue 7 | e1002180Figure 2. Quantitative 3C analysis confirms alternative loop formation between type I and type III latency types. 3C assay coupled
with quantitative PCR was used to analyze chromatin architecture of the EBV genome in type I (Mutu) and type III (Mutu-LCL) latencies. EBV genome
coordinates of all the Mse I fragments tested are indicated on the X-axis. A pink asterisk indicates fragment bearing the anchor primer. Loop
formation between the anchor primer (pink box) and an Mse I fragment is indicated by dashed arrows. Data were analyzed using the DCt method,
and Ct values generated by using 100 ng of EBV bacmid DNA Mse I digested and randomly ligated were used as the control. Data were obtained by
three independent experiments and expressed as mean 6 SE. Data generated by the anchor fragment self-ligation product were removed from
analysis. (A) Quantitative 3C analysis using the anchor primer within the fragment containing Qp and several regions of the EBV genome. (B)
Quantitative 3C analysis using the anchor primer within the fragment containing Cp and several regions of the EBV genome. (C) Quantitative 3C
analysis using the anchor primer within the fragment chosen as control and several regions of the EBV genome.
doi:10.1371/journal.ppat.1002180.g002
EBV Chromatin Conformation
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out to determine if CTCF was involved in chromatin loop
formation in EBV. To address this, we developed a new method,
which we refer to as 3C-ChIP, that combines 3C and ChIP to
address the role of a specific factor in mediating 3C linkages
(Fig. 4A). Specifically, cells were subject to formaldehyde cross-
linking for 30 min, followed by sonication and ChIP assay with
CTCF-specific antibody. The ChIP DNA was then end-repaired
by T4 DNA polymerase and ligated to its nearest cross-linked
neighbor. Anchor regions for CTCF sites at Qp (49500) or Cp-
CTCF (10350) were then used to design inverse PCR primers to
amplify cross-linked DNA by circular inverse PCR. The inverse
PCR-products were then analyzed by real time PCR using a 384-
well array that covers the entire genome of EBV. When Cp-CTCF
was used as the anchor in type I cells, we observed a peak at Cp
and another one at Qp (Fig. 4B left panel). The peak at Cp-CTCF
is mostly the self-ligated product generated during PCR
amplification. The peak at Qp suggests that a chromatin loop
exists between this region and the CTCF-binding site upstream of
Cp. In type III (Mutu-LCL) cell lines, we detected the self-ligation
product with Cp-CTCF, but also a strong peak at DS in the OriP
region, consistent with the loop observed from 3C data in type III
latency (Fig. 4B right panel). When Qp was used as the anchor, a
large self-ligation peak appeared, as expected (Fig. 4C). In addition
to the self-ligation, interactions between Qp and DS, and to a
lesser extent with Cp, were revealed in type I cells (Mutu) (Fig. 4C,
left panel). We also observed several minor peaks in the regions
around ,35500, ,68000 and ,138000 bp of the EBV genome.
Interestingly, these regions all correspond to CTCF binding sites,
which were mapped in a previous study [37]. In contrast, the Qp
anchor region produced only self-ligation in type III cells (Mutu-
LCL) (Fig. 4C right panel). None of the 3C-ChIP peaks were
observed when the cross-linking step was eliminated from the
protocol, indicating that these products are strictly dependent on
CTCF interactions (Fig. S5). These data support the conclusion
that DNA interactions between Qp and Cp are distinct in different
latency types, and that these interactions may be mediated by
CTCF.
Figure 3. Interaction between OriP binding factors and promoters correlates with promoter activation. ChIP-qPCR analysis of EBNA1,
ORC2, and TRF2 at target regions in type I (Mutu, blue) and type III (Mutu-LCL, red) type latency. Target regions were Cp (panel A), Qp (panel B), DS
(panel C), and OriLyt (panel D), as indicated. ChIP-qPCR was performed in conditions that preserved chromatin loop formation. Each bar represents
the mean 6 SE of three independent experiments. Data are expressed as fold enrichment of specific factor binding relative to that of an IgG control.
doi:10.1371/journal.ppat.1002180.g003
EBV Chromatin Conformation
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loop formation with OriP
To better study the role of CTCF in loop formation we
employed EBV bacmids carrying mutations for the CTCF binding
site at Qp and Cp. (Fig. 5A). We have previously shown that the
mutations disrupting CTCF binding at either Qp or Cp alter viral
transcription control and promoter selection in 293 cells [37,54].
We therefore introduced the Wt, the DCTCF-Qp and the
DCTCF-Cp bacmid in 293 cells and generated a stable cell line
by selecting for hygromycin resistance and GFP expression.
Consistent with a previous study, both DCTCF-Qp and DCTCF-
Cp cells adopted a type III latency type expression profile with
high levels of EBNA2 expression, Cp promoter activation, and Qp
transcription repression, while Wt Bacmids adopted a type I
latency expression pattern, which is typical of EBV in 293 cells
[58] (Fig. 5B and S6). To examine the contribution of CTCF at
Qp and Cp on EBV chromatin architecture, we compared Wt and
DCTCF genomes using 3C assays (Fig. 5C and D). In Wt cells, we
found that Qp is able to establish a strong interaction with OriP
and CTCF-Cp (Fig. 5C, top panel), similar to the loop observed in
Mutu I cell lines (Fig. 1). Interestingly, in DCTCF-Qp and
DCTCF-Cp cells, loop formation was not detected between Qp
and either OriP or CTCF-Cp binding site (Fig. 5C, middle and
lower panels). When Cp was used as anchor primer, loop
Figure 4. Chromosome Conformation Capture Chromatin Immunoprecipitation (3C-ChIP) analysis shows that CTCF is involved in
chromatin looping in EBV. A) Schematic description of the 3C-ChIP assay used for analysis of CTCF mediated interactions with the EBV genome. B
and C) 3C-ChIP assay using either Cp-CTCF anchor primers (panels B) or Qp anchor primers (panels C) with Mutu (left panel) or Mutu-LCL (right panel).
Anchor primer regions are indicated by an asterisk. EBV genome coordinates of EBV 384-well genome array are indicated on the X-axis. Data are
representative of two independent experiments and are expressed as fold enrichment of CTCF binding over that of an IgG control. Only data with a
SD less then 10% were considered.
doi:10.1371/journal.ppat.1002180.g004
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(Fig. 5D, middle panel), similar to the loop that was observed in type
III Mutu LCL (Fig. 1). This interaction was not detected in Wt
bacmid in 293 cells (Fig. 5D, top panel), consistent with Wt cells
having a type I phenotype. Surprisingly, Cp was not able to form
any loop in DCTCF-Cp cells (Fig. 5D, lower panel), suggesting that
CTCF at Cp is necessary for the long-distance interaction with
OriP. However, loss of CTCF binding had a net positive effect on
Cp transcription, perhaps reflecting the ability of CTCF to insulate
OriP enhancer activation at Cp. Control anchor primers (35401–
36017) showed no significant loop formation in these assays,
indicating that these 3C interactions are specific (Fig. S7).
These 3C assays were repeated using different primer sets for
more quantitative real-time PCR analysis of the 3C products
(Fig. 6). Analysis of the Qp anchor interaction pattern confirmed
the loop formation between OriP and the CTCF-Cp binding site
in Wt EBV bacmid containing cell lines, but not in DCTCF-Qp
and DCTCF-Cp bacmid genomes (Fig. 6A). Interestingly, in
DCTCF-Qp cell lines a weak interaction was observed with the
region at 41000 (Fig. 6A). Analysis of the Cp anchor region
showed interactions between the Cp region and OriP in DCTCF-
Qp but not in the Wt or DCTCF-Cp (Fig. 6B). The control anchor
primer did not form any significant peaks at OriP or CTCF-Cp or
Qp (Fig. 6C). These data suggest that CTCF binding at Qp and at
Figure 5. Mutation in the CTCF binding site at Qp and at Cp alters chromatin conformation and promoter activation. (A) Schematic
representation of the EBV genome around the Cp and Qp promoters in the Wt and mutant bacmids. A red dashed line represents mutations that
abolish CTCF binding. Green circles indicate known CTCF binding sites. (B) Analysis of mRNA expression for EBNA1 and EBNA2 gene and promoter
utilization by RT-qPCR. Data are normalized to GFP protein and expressed as log22
DDCt . Each bar represents the mean 6 SE of three independent
experiments. (C) Representative gel images of 3C PCR analysis using the anchor primer within the fragment containing Qp promoter and several
regions of EBV genome for Wt (top panel) or DCTCF-Qp (middle panel) or DCTCF-Cp (lower panel). (D) Representative gel imagine of 3C PCR analysis
using the anchor primer within the fragment containing Cp promoter and several regions of the EBV genome for Wt (top panel) or DCTCF-Qp (middle
panel) or DCTCF-Cp (lower panel).
doi:10.1371/journal.ppat.1002180.g005
EBV Chromatin Conformation
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OriP, as well as restricting loop formation between Cp and OriP in
293 cell lines. Moreover, loop formation is correlated with
promoter transcription activation at Qp.
OriP binding factors EBNA1, ORC2, and TRF2, interact
with Wt-Qp but not DCTCF-Qp
We next investigated if OriP binding factors, EBNA1, ORC2
and TRF2, can interact with either Cp or Qp through loop
Figure 6. Quantitative 3C analysis confirms changes in chromatin architecture in DCTCF-Qp and DCTCF-Qp compared to Wt EBV
bacmid. 3C assay coupled with quantitative PCR was used to analyze EBV chromatin architecture in 293-EBV Wt bacmid, 293-EBV DCTCF-Qp and
293-EBV DCTCF-Cp stable cell lines. EBV genome coordinates of all the MseI fragments tested are indicated on the X-axis. A pink asterisk indicates the
fragment bearing the anchor primer. Loop formation between the anchor primer (pink box) and a MseI fragment is indicated by dashed arrows. PCR
amplification was analyzed using the DCt method, and Ct values generated by using 50 ng of EBV bacmid DNA Mse I digested and randomly ligated
were used as the control. Data were obtained by three independent experiments and expressed as mean 6 SE. Data generated by the anchor
fragment self-ligation product were removed from analysis. (A) Quantitative 3C analysis using the anchor primer within the fragment containing Qp
and several regions of the EBV genome. (B) Quantitative 3C analysis using the anchor primer within the fragment containing Cp and several regions
of EBV genome. (C) Quantitative 3C analysis using the anchor primer within the fragment chosen as control and several regions of the EBV genome.
doi:10.1371/journal.ppat.1002180.g006
EBV Chromatin Conformation
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method for the ChIP assay (Fig. 7). We found that EBNA1,
ORC2, and TRF2 were enriched at Cp in DCTCF genomes, but
not in Wt cells (Fig. 7A), consistent with Cp activation in DCTCF
cells. In contrast, EBNA1, ORC2, and TRF2 were enriched at Qp
in Wt relative to DCTCF cells (Fig. 7B), consistent with Qp
activation in Wt cells. EBNA1 binding at Qp was also reduced in
DCTCF genomes, suggesting that CTCF can affect EBNA1
binding at Qp. We also evaluated the binding of EBNA1, ORC2,
and TRF2 at DS (Fig. 7C). While EBNA1, ORC2, and TRF2
bound DS in Wt cells, binding was reduced in DCTCF-Qp cells,
perhaps reflecting cooperative interactions between Qp and DS
mediated by CTCF and chromatin looping. No significant binding
of EBNA1, ORC2, or TRF2 was detected at the negative control
OriLyt region (Fig. 7D). We also confirmed that CTCF binding at
Qp was enriched in Wt and eliminated in DCTCF-Qp genomes,
as expected (data not shown). These findings support the model
that CTCF binding at Qp mediates interactions with OriP in type
I latency.
Depletion of CTCF affects the three-dimensional
organization of the EBV genome
To determinate if CTCF levels in cells can influence chromatin
loop formation 293-EBV Wt cell lines were transfected with
siRNA against CTCF (siCTCF) or non-targeting control (siCon-
trol). We used 293-EBV positive cell lines because of their high
transfection efficiency compared to human B cells (Fig. 8). siCTCF
transfection completely depleted CTCF levels in 293-EBV Wt cells
compared to siControl (Fig. 8A). By real time RT-PCR we
investigated the effect of siCTCF transfection on promoter
utilization and viral genome expression (Fig. 8B). We observed
that CTCF depletion caused a moderate increase in Cp activation
and a slight decrease in Qp transcription. However, neither
EBNA1 nor EBNA2 mRNA levels were significantly affected by
siCTCF. 3C analysis was then carried out to determine the effect
of siCTCF on chromatin architecture. In 293-EBV Wt cells
transfected with siControl we were able to observe chromatin loop
formation between Qp and OriP (Fig. 8C, top panel). Interest-
ingly, the chromatin loop between Qp and OriP was completely
Figure 7. Absence of chromatin loop formation correlates with a loss of interaction between OriP binding factors ORC2 and TRF2 at
Qp. ChIP-qPCR analysis of EBNA1, ORC2 and TRF2 at target regions in Wt and DCTCF EBV-positive 293 stable cell lines. ChIP-qPCR was performed in
conditions that preserved chromatin loop formation. Each bar represents the mean 6 SE of three independent experiments. Data are expressed as
fold enrichment of specific factor binding relative to that of an IgG control. Target regions used for PCR amplification were Cp (panel A), Qp (panel B),
DS (panel C), and OriLyt (panel D).
doi:10.1371/journal.ppat.1002180.g007
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Consistent with previous observations, no chromatin loop was
detected when Cp was used as the anchor primer in these EBV-
293 cell lines (Fig. 8D). 3C assay coupled with real time PCR
analysis was then employed to better quantify our analysis (Fig. 8E).
Real time PCR confirmed that Qp-OriP interaction was
significantly reduced in siCTCF but not in siControl transfected
cells (Fig. 8E), left panel. No significant peaks were observed when
Figure 8. CTCF siRNA depletion disrupts chromatin architecture of EBV. (A) 293-EBV Wt cell lines were transfected with siRNA against CTCF
(siCTCF) or a non-targeting control (siControl). After 72 hrs cells were harvested and then analyzed by western blot with antibody to CTCF (top panel)
or loading control PCNA (lower panel) to check depletion efficiency. (B) RT-qPCR analysis of promoter utilization and EBNA1 and EBNA2 gene
expression after CTCF depletion. Data are normalized to GFP mRNA and expressed as 2DDCt values. Each bar represents the mean 6 SE of three
independent experiments. (C and D) 3C assay was used to analyze chromatin conformation after depletion of CTCF. Representative gel images of 3C
PCR analysis using the anchor primer within the fragment containing Qp promoter (C) or Cp promoter (D) and several regions of the EBV genome for
293-EBV Wt cell line transfected with siControl or siCTCF siRNA. Amplified regions are indicated above each gel. (E) 3C assay coupled with quantitative
PCR was used to analyze EBV chromatin architecture in 293-EBV Wt bacmid transfected with siControl or siCTCF siRNA, using the anchor primer
within the fragment containing Qp promoter (left panel) or Cp promoter (right panel) and several regions of EBV genome. EBV genome coordinates
of all the Mse I fragments tested are indicated on the X-axis. A pink asterisk indicates fragment bearing the anchor primer. Loop formation between
anchor primer (pink box) and a Mse I fragment is indicated by dashed arrows. PCR amplification was normalized by using 50 ng of EBV bacmid DNA
Mse I digested and randomly ligated. Data were obtained by three independent experiments and expressed as mean 6 SE. Data generated by the
anchor fragment self-ligation product were removed from analysis.
doi:10.1371/journal.ppat.1002180.g008
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The control anchor primer did not form any significant chromatin
loops with OriP or Cp or Qp regions (Fig. S8). These data indicate
that CTCF is critical for the establishment and maintenance of the
OriP-Qp chromatin loop in EBV-transfected 293 cell lines.
Discussion
Chromatin structure is known to play an important role in gene
expression by regulating the accessibility of the DNA to
transcription factors and RNA polymerase II. Emerging evidence
shows that not only the composition of the chromatin fiber, but
also the three-dimensional structure of chromatin can influence
gene transcription. We and others have shown that epigenetic
features, including chromatin structure, play an important role in
regulating EBV gene expression during latency [21,34,37,54,59].
We have also reported that the chromatin-organizing factor
CTCF binds at Cp and Qp, and is important for maintaining the
appropriate epigenetic pattern and transcription control at these
promoters [37,58]. Here, we explored the hypothesis that different
latency types correspond to distinct chromatin conformations.
Using 3C methodology, we found that different latency types form
distinct chromatin-loops (Fig. 1 and 2). We identified two mutually
exclusive loops that form between either OriP and Qp or OriP and
Cp. These alternative loops correlate with promoter activity in
their respective latency types. Genetic and siRNA depletion studies
demonstrated that CTCF binding is essential for loop formation.
We propose that chromosome conformation is an important
epigenetic feature of latency type, and that CTCF plays a central
role in generating EBV chromosome conformation (Fig. 9).
CTCF has been implicated in chromatin loop formation in
multiple species and chromosome contexts [46]. CTCF binds
upstream of Qp and Cp in both type I and type III latency,
although with some reduced occupancy at Cp in type III latency
[37]. Biochemical methods used in this study suggest that CTCF is
intimately involved in loop formation between OriP and either Cp
or Qp. Using the 3C-ChIP assay, we show that the CTCF at Cp is
in close physical proximity to Qp in type I and to DS in type III
(Fig. 4B). Similarly, we found that CTCF bound at Qp was in close
proximity to DS in type I, but not in type III (Fig. 4C). We also
observed that Qp contacts several other regions of the EBV
genome, suggesting that EBV genome architecture may be more
complex than a single loop between OriP and either Cp or Qp. It
is also likely that CTCF links multiple sites in a hub to create more
intricate chromatin structures, as has been shown in other model
systems [46,48]. The use of the 3C-ChIP assay may help to
elucidate some of these more complex interactions within the EBV
chromosome.
Genetic methods were also used to address the role of CTCF in
EBV chromatin conformation (Figs. 5–7). EBV bacmids carrying a
mutation in the CTCF binding sites at either Qp or Cp revealed a
strong correlation between loop formation and promoter activa-
tion. Previously, we showed that the DCTCF-Qp bacmids have a
decrease in Qp utilization and a corresponding increase in EBNA2
gene expression [37]. Here, using 3C methods, we found that
DCTCF-Qp bacmids fail to form a loop between OriP and Qp,
while Wt bacmids form these loops (Fig. 5C and 6A). Moreover,
DCTCF-Qp bacmids formed an alternative loop between OriP
and Cp, suggesting that the failure to form a type I conformation
(Qp-OriP) resulted in a type III conformation (Cp-CTCF)
(Fig. 5D). The biological implications of this finding are not
immediately clear, but suggest that the natural evolution of EBV
towards a type I latency requires the ability to form a loop between
OriP and Qp, which is mediated by CTCF binding sites.
Interestingly, CTCF binding at Cp was also essential for Qp-
OriP loop formation, since CTCF-DCp bacmids failed to form the
OriP-Qp loop, as well as the OriP-Cp loop (Fig. 5D and 6B). This
suggests that CTCF (Cp)-CTCF (Qp) interactions may be
important for long-distance loop formation between OriP and
Qp (Fig. 9). Consistent with this model, siRNA depletion of CTCF
led to a complete loss of all measurable loop formation at either
Qp or Cp (Fig. 8), suggesting that CTCF is generally required for
chromosome conformations measured at these loci.
Other factors, in addition to CTCF, must also contribute to
loop formation and promoter selection. Components of OriP are
known to contribute to viral chromosome conformation during
latency. EBNA1, TRF2, and ORC bind to OriP in both type I and
III latency, and have been implicated in chromosome structure
[57,60]. In experiments with extended cross-linking, we showed
that EBNA1, TRF2, and ORC are in close proximity to the active
promoter, namely Cp in type III and Qp in type I (Fig. 3). EBNA1
is known to form homotypic interactions through its linking
regions, and is an essential transcription activator of Cp during B-
cell immortalization [28,61]. Although not directly tested in this
study, it seems likely that EBNA1 will be required for loop
formation between OriP and Qp. In some 3C experiments, we
observed more efficient linkage of Cp to the DS region relative to
the FR region (Fig. 2B). This may be due to the additional
Figure 9. Model of chromatin conformational control of EBV latency types. A) Linear model of EBV latency types depicting OriP enhancer
interactions with Cp (type III) or Qp (type I). CTCF binding sites are shown as a yellow box with an arrow. B) Conformational model showing OriP
recruiting Qp into an active loop and domain in type I cells (top panel), and the alternative conformation where OriP recruits Cp into a loop and active
domain in type III cells (lower panel).
doi:10.1371/journal.ppat.1002180.g009
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due to the proximity and orientation of DS to Cp. However,
EBNA1 is known to promote looping between DS and FR in vitro
[62,63], suggesting that OriP elements are likely to interact with
each other and function coordinately in vivo. In addition, the FR
can function as an EBNA1-dependent transcriptional enhancer
[28,29,30,64,65]. Since our 3C data can not readily dissect the
relative contributions of FR and DS to loop formation, we suggest
that OriP functions as a single structural element that forms stable
chromatin loops with either Cp in type III or Qp in type I latency.
Chromatin loop structure is likely to be an important epigenetic
regulatory component of EBV latency gene expression. How these
different loops and conformations are selected remains an
important unanswered question. We have shown the CTCF is
one essential component required for the establishment and
maintenance of DNA loops that form between the OriP enhancer
and the promoters at Cp and Qp. EBNA1, and components of
OriP, must also be important for these interactions. It is also likely
that other epigenetic modifications, including histone tail modi-
fications and DNA methylation, contribute to loop formation,
chromatin conformation, and promoter selection. DNA methyl-
ation of Cp is known to play a central role in the transcriptional
silencing of Cp in type I latency [21,34,36,58,66,67]. Furthermore,
DNA methylation is known to inhibit CTCF binding at some sites,
and the Cp CTCF binding site may be sensitive to changes in
DNA methylation. In addition to changes in CTCF DNA binding,
variation in CTCF protein levels may also contribute to promoter
selection and loop formation [54]. CTCF is also known to be
subject to several post-translational modifications, which may also
contribute to selective loop formation [68,69,70]. Although the
precise molecular mechanism of loop formation and promoter
selection is not yet elucidated, our findings provide strong evidence
that EBV chromatin conformation is an important structural
component of latency type determination and, more generally, the
establishment of stable epigenetic fates.
Methods
Cells
293 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum and
antibiotic in a 5% CO2 incubator at 37uC. EBV positive Mutu I
and Mutu-LCL were cultured in suspension in RPMI 1640
medium supplemented with 10% fetal bovine serum and
antibiotics in a 5% CO2 incubator at 37uC. Mutu-LCL were
established by primary infection of peripheral blood mononuclear
cells (PBMC) with EBV virions generated from stimulated Mutu I
cells. 293-EBV Wt, DCTCF-Qp, and DCTCF-Cp have been
previously described [37,54] and were cultured as adherent cells in
DMEM supplemented with 10% fetal bovine serum and 100 mg/
liter hygromycin B in 5% CO2 incubator at 37uC. 293-EBV Wt
carry a bacmid containing the EBV genome and express a green
fluorescent protein (GFP) and hygromycin B drug resistance gene.
293-EBV DCTCF-Qp cells carry a bacmid containing the EBV
genome mutated at the CTCF binding site at 50082 and express a
green fluorescent protein (GFP) and hygromycin B drug resistance
gene [37]. 293-EBV DCTCF-Cp cells carry a bacmid containing
the EBV genome deleted at the CTCF binding site at 10393–
10590 and express a green fluorescent protein (GFP) and
hygromycin B drug resistance gene [54].
Chromosome Conformation Capture (3C) assay
3C assay followed the protocol from Hage `ge et al. [71], with
minor modifications. EBV-positive cells were filtered through a
70 mm to obtain a single cell preparation. 1610
7 cells were then
fixed in 1% formaldehyde for 30 min at room temperature.
30 min cross-linking was found to be optimal since 10 min cross-
linking resulted in few detectable 3C products (data not shown).
The reaction was quenched with 0.125 M glycine and cells
were collected by centrifugation at 230 g at 4uC. The pellet was
resuspended in 0.5 ml cold lysis buffer (10 mM Tris-HCl,
pH 7.5; 10 mM NaCl; 5 mM MgCl2; 0.1 mM EGTA) with
freshly added 16 complete protease inhibitors (Roche) and was
lysed on ice for 10 min. The nuclei were collected by
centrifugation at 500 g for 10 min at 4uC and were resuspended
in 0.5 ml of 1.46Mse I buffer (New England Biolabs), including
0.3% SDS and were incubated for 1 h at 37uC while shaking at
1200 rpm. 2% (final concentration) Triton X-100 was added to
the nuclei and then the samples were incubated for 1 hr at 37uC
while shaking. 500 U Mse I (50,000 U/ml New England Biolabs)
was added to the nuclei and the samples were incubated at 37uC
over night while shaking. 10 ml of the samples were collected
before and after the Mse I reaction to evaluate digestion
efficiency. The reaction was stopped by addition of 1.6% SDS
(final concentration) and incubation at 65uC for 30 minutes
while shaking at 1200 rpm. The sample was then diluted 10 fold
with 1.36ligation Buffer (Roche) with added 1% Triton X-100
and was incubated for 1 h at 37uCw h i l es h a k i n ga t9 0 0r p m .
100 U T4 DNA ligase (5 U/ml Roche) were added to the sample
and the reaction was carried at 16uC for 4 hrs followed by
45 min at room temperature. 300 mg of Proteinase K were added
to the sample and the reaction was carried at 65uC overnight.
RNA was removed by adding 300 mg of RNAse and incubating
the sample for 1 h at 37uC. DNA was purified by twice phenol-
chloroform extraction and ethanol precipitation. Purified DNA
was then analyzed by conventional or quantitative PCR. As
control for ligation products EBV Wt bacmid was digested with
10 U of Mse I overnight and then incubated with 10 U T4
DNA-ligase at 16uC overnight. The DNA was extracted by
phenol-chloroform and precipitated with ethanol. Purified DNA
was then analyzed by conventional or quantitative PCR. For
Real time PCR, the DCt method was applied for analyzing data,
using EBV-bacmid Ct values as control. Ct values were
normalized for each primer pair by setting the Ct value of
100 ng of EBV bacmid control random ligation matrix DNA at a
value of 1. Primer sequences for conventional PCR are listed
in Table S1. Primer sequences for quantitative PCR are listed
in Table S2.
Chromatin Immunoprecipitation (ChIP) assay
ChIP assay followed the protocol provided by Upstate Biotech-
nology, Inc., with minor modifications as previously described [37].
Additional modifications are as follows. Cells were fixed in 1%
formaldehyde for 30 minutes. DNAs were sonicated to between
200- and 350-bp DNA fragments on a Diagenode Bioruptor
according to the manufacturer’s protocol, and real-time PCR was
performedwithSYBER green probe inan ABI Prism 7000 using1/
100 to 1/2,500 of the ChIP DNA according to the manufacturer’s
specified parameters. Chromatin was immunoprecipitated using
polyclonal antibodies for CTCF (Millipore), ORC2 (Pharmigen),
EBNA1 (which was raised against full-length EBNA1), and TRF2 (
which was raised against full-length TRF2). The primers for
amplification were as follows: DS (atgtaaataaaaccgtgacagctcat
and ttacccaacgggaagcatatg), and OriLyt (gcccgttgggtttcattaag and
ccaaatctcgcggacctcta) and Qp (ggctcacgaagcgagac and acaggac-
ctgcgttatagcc) and Cp (gccgtggaaaaaaatttatgg and cgccaacaaggtt-
caattttct).
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Immunoprecipitation (3C-ChIP) assay
EBV positive cells were fixed in 1% formaldehyde for
30 minutes at room temperature. The reaction was quenched by
adding 0.125 M glycine (final concentration) and the cells were
collected by centrifugation at 400 g for 5 min, washed twice with
PBS and then 1610
7 were resuspended in 1 ml cold lysis buffer
(1% SDS; 10 mM EDTA; 50 mM Tris-HCl, pH 8) with 16
complete protease inhibitors (Roche) and lysed on ice for 10 min.
DNA was sonicated to between 200- and 350-bp DNA fragments
on a Diagenode Bioruptor according to manufacturer’s protocol.
100 ml sonicated cell lysate were then diluted 10 fold with
immunoprecipitation (IP) buffer (0.01% SDS; 1.1% Triton X-100;
1.2 mM EDTA; 16.7 mM Tris-HCl, pH 8; 167 mM NaCl) and
then pre-cleared by adding 50 ml 50% pre-blocked Protein A
containing 25 mg of the heat-denaturated ssDNA and the samples
were incubated for 30 min at 4uC with gentle rotation. The
mixture was then centrifuged for 5 min at 750 g at 4uC and then
the supernatant was carefully transferred into a new tube.
Chromatin was precipitated by incubating the samples with
2.5 mg of antibody for CTCF (Millipore) or normal rabbit IgG
(Santa Cruz) as negative control overnight at 4uC with rotation.
Immune complexes were collected by incubation with 50 ml 50%
slurry protein A sepharose beads (GE Healthcare) for 3 hrs at 4uC
with rotation. Beads were collected by centrifugation at 800 g for
2 min and the washed once with 1 ml Low Salt buffer (0.1%SDS;
1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8;
150 mM NaCl), then once with 1 ml High Salt buffer
(0.1%SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl,
pH 8; 500 mM NaCl), then once with 1 ml LiCl buffer (250 mM
LiCl; 1% NP-40; 1% Na-deoxycolate; 1 mM EDTA; 10 mM
Tris-HCl, pH 8.0). Proteinase inhibitors cocktail (Sigma) was
added to all the washing buffers before use. Before to eluting the
immune complexes from beads we repaired the DNA ends
generated by sonication in order to be ligated by T4 DNA ligation.
The protein A beads were collected after the last wash by
centrifugation at 800 g for 5 min and then resuspended into
100 ml kinase buffer [50 mM Tris-HCl, pH 7.5; 10 mM MgCl2;
1 mM DTT; 1 mM ATP; 35 mM dNTP; 6 U Klenow enzyme
(Roche); 5 U T4 polynucleotide Kinase (Roche); 5 U T4 DNA
polymerase (Roche)] and incubate for 90 minutes at 37uC with
while shaking. The beads were centrifuged at 800 g for 3 minutes
and then resuspended in 1 ml of 16Ligation buffer (Roche) and
50 U T4 DNA ligase were added. The samples were then
incubated at 16uC while shaking overnight. The beads were
collected by centrifugation, washed twice with 1 ml TE and then
resuspended in 150 ml Elution Buffer (1%SDS/TE) and incubated
for 30 minutes at 65uC while shaking. The beads were centrifuged
at 800 g for 5 minutes and the supernatant was carefully
transferred into a new tube and incubated at 65uC overnight.
Samples were then incubated with 45 mg Proteinase K for 3 hours
at 50uC. After twice phenol/chloroform extraction and ethanol
precipitation, purified DNA was amplified by nested PCR. For the
first-round amplification we used High fidelity PlatinumTaq DNA
Polymerase (Invitrogen) according to the manufacturer. The PCR
conditions were the following: 94uC for 2 min followed by 35
cycles of 94uC for 30 s, 55uC for 30 s and 68uC for 1 min. For the
second-round PCR 100 ng of first-round PCR DNA was used as
template for Taq DNA polymerase (Roche). PCR conditions were
the following: 94uC for 2 min followed by 30 cycles of 94uC for
30 s, 55uC for 30 s and 72uC for 1 min. Nested inverse primer
sequences for both first and second round PCR are listed in Table
S3. DNA generated by nested PCR was then analyzed by
quantitative EBV-genome wide 384-well array.
RNA extraction and RT-PCR
RNA was extracted from 5610
6 cells using the Qiagen RNA
Extraction Kit according to the manufacturer’s protocol (Qiagen).
After extraction, the RNA was incubated with 2 U DNAse I at
37uC for 30 minutes, followed by the inactivation of the enzyme at
65uC for 10 minutes. The RNA was quantified and 2 mg of RNA
was reverse transcribed using Super Script II Reverse Transcrip-
tase from Invitrogen. 50 ng of cDNA was then analyzed by real
time PCR, using the DCt method, using GFP gene as the internal
control. Primer sequences are listed in Table S4.
siRNA mediated knockout of CTCF
293 cells containing EBV bacmid, at the density of 2610
6 cells
in 10 cm plate, were transfected with 50 pmol of short interfering
RNA (siRNA) targeting CTCF (siD-020165-19) or non-targeting
siRNA (si D-001810-01) (Dharmacon) as control, using Dharma-
FECT transfection reagent, according to manufacture’s protocol.
After 3 days post transfection cells were treated for 3C analysis as
described above. Knockout efficiency was evaluated by western
blot analysis.
Supporting Information
Figure S1 Primers validation for Real time PCR
analysis of 3Cassay. Primers used for Real time analysis of
3C assay were validated by agarose gel electrophoresis and
ethidium bromide stain. EBV DNA bacmid digested with MseI
and ligated were amplified used conventional PCR. PCR
amplification products were visualized on 3% Nusieve agarose gel.
(TIF)
Figure S2 Dissociation curve analysis for Qp anchor
primer sets. Dissociation curve analysis for Qp primer sets using
EBV DNA bacmid digested with MseI and ligated was performed
after a completed Real time PCR to exclude non specific products
and primer dimers. Graph displays a plot of the first derivative of
the rate of change in fluorescence as a function of temperature.
(TIF)
Figure S3 Dissociation curve analysis for Cp anchor
primer sets. Dissociation curve analysis for Cp primer sets using
EBV DNA bacmid digested with MseI and ligated was performed
after a completed Real time PCR to exclude non specific products
and primer dimers. Graph displays a plot of the first derivative of
the rate of change in fluorescence as a function of temperature.
(TIF)
Figure S4 Dissociation curve analysis for Control
anchor primer sets. Dissociation curve analysis for Control
primer sets using EBV DNA bacmid digested with MseI and
ligated was performed after a completed Real time PCR to
exclude non specific products and primer dimers. Graph displays a
plot of the first derivative of the rate of change in fluorescence as a
function of temperature.
(TIF)
Figure S5 Control for 3C-ChIP assay. Samples were treated
identically to 3C-ChIP assays shown in Fig. 4 with the exception of
formaldehyde cross-linking which was excluded from these control
reactions.
(TIF)
Figure S6 Gene expression profile of 293-EBV wt and
DCTCF bacmids. Analysis of mRNA expression for EBNA1
and EBNA2 gene and promoter utilization by RT-qPCR. Data
are normalized to GFP RNA and expressed as 2
2DCt. Each bar
represents the mean 6 SE of three independent experiments.
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Figure S7 Control for 3C assays with bacmids. Samples
from Fig. 5 were assayed with anchor primers in the control region
at 35401.
(TIF)
Figure S8 Control for 3C assays with siRNA transfected
bacmids. Samples from Fig. 8 were assayed with anchor primers
in the control region at 35401 by conventional PCR (A) and
quantitative PCR (B).
(TIF)
Table S1 Primers sequence for conventional PCR analysis of 3C
products.
(DOC)
Table S2 Primers sequence for real time PCR analysis of 3C
products.
(DOC)
Table S3 Primers sequence for nested inverse PCR analysis of
3C-ChIP products.
(DOC)
Table S4 Primer list for RT-PCR.
(DOC)
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